Molecular Medicine and Gene Therapy, Lund Strategic Center for Stem Cell Biology, Lund University, Lund, Sweden.
Blood. 2011 Dec 1;118(23):6087-96. doi: 10.1182/blood-2011-08-371963. Epub 2011 Oct 11.
Diamond-Blackfan anemia (DBA) is a congenital erythroid hypoplasia caused by a functional haploinsufficiency of genes encoding for ribosomal proteins. Among these genes, ribosomal protein S19 (RPS19) is mutated most frequently. Generation of animal models for diseases like DBA is challenging because the phenotype is highly dependent on the level of RPS19 down-regulation. We report the generation of mouse models for RPS19-deficient DBA using transgenic RNA interference that allows an inducible and graded down-regulation of Rps19. Rps19-deficient mice develop a macrocytic anemia together with leukocytopenia and variable platelet count that with time leads to the exhaustion of hematopoietic stem cells and bone marrow failure. Both RPS19 gene transfer and the loss of p53 rescue the DBA phenotype implying the potential of the models for testing novel therapies. This study demonstrates the feasibility of transgenic RNA interference to generate mouse models for human diseases caused by haploinsufficient expression of a gene.
先天性红细胞生成不良性贫血(DBA)是一种由核糖体蛋白基因功能单倍不足引起的先天性红细胞生成减少症。在这些基因中,核糖体蛋白 S19(RPS19)突变最为频繁。由于疾病表型高度依赖于 RPS19 下调的程度,因此生成像 DBA 这样的疾病的动物模型具有挑战性。我们使用转基因 RNA 干扰技术生成了用于 RPS19 缺陷型 DBA 的小鼠模型,该技术可实现 Rps19 的诱导和分级下调。Rps19 缺陷型小鼠表现出巨细胞性贫血,同时伴有白细胞减少症和血小板计数的变化,随着时间的推移,这会导致造血干细胞耗竭和骨髓衰竭。RPS19 基因转移和 p53 的缺失均可挽救 DBA 表型,这意味着这些模型具有测试新型疗法的潜力。本研究证明了转基因 RNA 干扰生成由基因单倍不足表达引起的人类疾病小鼠模型的可行性。